Full Text View
Tabular View
No Study Results Posted
Related Studies
Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP)
This study is currently recruiting participants.
Verified by Children's Hospitals and Clinics of Minnesota, September 2008
First Received: September 11, 2008   Last Updated: March 19, 2009   History of Changes
Sponsored by: Children's Hospitals and Clinics of Minnesota
Information provided by: Children's Hospitals and Clinics of Minnesota
ClinicalTrials.gov Identifier: NCT00751647
  Purpose

The purpose of this project is to determine the short-term effects of a customized Core Strengthening and Respiratory Exercise Program (CSREP) on children with cystic fibrosis (CF) between the ages of 10 and 21 who are receiving outpatient care at Children's Hospitals and Clinics of Minnesota. The CSREP, which will be provided by a physical therapist and a physical therapist assistant, consists of specific breathing techniques and core strengthening exercises, designed to improve rib cage mobility, pulmonary function, aerobic capacity, posture, and core strength. Currently the CF population at Children's receives physical therapy on an inpatient basis only.

The overall goal of this program is to prove the viability of an outpatient exercise program for this population. Specific aims include:

  • To customize a CSREP protocol per each patient
  • To measure patient outcomes at baseline and six months
  • To develop a satisfaction tool in order to measure patient experience and satisfaction

Condition Intervention Phase
Cystic Fibrosis
Other: Physical Therapy
Phase II

Genetics Home Reference related topics: cystic fibrosis
MedlinePlus related topics: Cystic Fibrosis Exercise and Physical Fitness
U.S. FDA Resources
Study Type: Interventional
Study Design: Supportive Care, Open Label, Single Group Assignment, Efficacy Study
Official Title: Cystic Fibrosis Core Strengthening and Respiratory Exercise Program (CSREP)

Further study details as provided by Children's Hospitals and Clinics of Minnesota:

Primary Outcome Measures:
  • Pulmonary function, aerobic capacity, rib cage mobility, posture, and core strength, thus warranting more extensive study and development. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: December 2008
Estimated Study Completion Date: January 2010
Estimated Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A1
Population receiving the CF specific outpatient PT services.
Other: Physical Therapy
Treatment

Detailed Description:

Study Design: Phase II clinical trial.

Objective: To determine whether a customized physical therapy exercise intervention titled Core Strengthening and Respiratory Exercise Program (CSREP) clinically improves the following outcome measures for children between the ages of 10 and 21 with cystic fibrosis: pulmonary function, aerobic capacity, rib cage mobility, posture, and core strength, thus warranting more extensive study and development.

Background: Previous research conducted in pediatric populations has focused on the effects of aerobic training, anaerobic training, and strengthening of the extremities on the health of children with cystic fibrosis. However, the disease process of cystic fibrosis secondarily causes impairments in the musculoskeletal and nervous systems. No intervention study aimed at positively impacting these systems has been done to date with children with cystic fibrosis.

Methods: A 6-month CSREP will be customized to meet the specific needs of each participant. During Part I of the program participants will attend weekly CSREP treatments for 4 to 6 weeks; in Part II they will attend monthly CSREP treatments over a five-month period. Each session will last for 45-60 minutes. During these treatments, participants will be given instruction on a daily home exercise program and will receive hands on physical therapy interventions. Handouts with pictures and how-to instructions for assigned exercises will be provided. Participants will be given calendars to track completion of home exercises and level of compliance. During Part II, a researcher will call participants every week in order to encourage compliance with the home exercise program and to provide clarification as needed. All participants will continue to receive regular medical care as well as PT treatments.

A respiratory therapist will perform the pulmonary function tests, a respiratory therapist along with an exercise physiologist will perform the VO2max testing, and a physical therapist will perform the physical therapy evaluation, including assessment of rib cage mobility, core strength, and posture.

Another physical therapist as well as a physical therapist assistant will provide the physical therapy treatments, instruct the participants in their home program, and make the weekly phone calls to all participants.

An experience survey will be designed to evaluate both satisfaction on a scale of 1 to 10 and self scoring of outcome measures including: respiratory function, cough strength, activity tolerance, posture, and strength on a three point Likert scale of: 1) Got worse; 2) Stayed the same; and 3) Got better. Additionally, the survey will include a question on the likelihood of continuing with the home program after the study has ended. The survey will be administered at 6 months upon completion of the program.

Relevance: The results of this inquiry as to the viability of the CSREP will prove relevant to the above-mentioned patient outcomes within the cystic fibrosis population. The customized CSREP protocol will provide a non-pharmacological outpatient treatment option that can be completed on an outpatient basis, independently, in the patient's home.

  Eligibility

Ages Eligible for Study:   10 Years to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Children with cystic fibrosis receiving outpatient care from Children's Cystic Fibrosis Clinic
  • Aged 10-21
  • Living within a 35-mile radius of Children's Minneapolis, who agree to participate.

Exclusion Criteria:

  • Children with co-morbid conditions in which the exercise program is contra-indicated will be excluded from this study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00751647

Contacts
Contact: Mahrya A Johnson 612-813-6384 mahrya.johnson@childrensmn.org
Contact: Julie Christiansen 612-813-6376 julie.christiansen@childrensmn.org

Locations
United States, Minnesota
Children's Hospitals and Clinics of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55404
Contact: Laurie Blumberg-Romero, MA     612-813-7628     laurie.blumberg-romero@childrensmn.org    
Contact: Mahrya A Johnson, BA, CCRP     612-813-6384     mahrya.johnson@childrensmn.org    
Sub-Investigator: John McNamara, MD            
Principal Investigator: Katie Fenlon            
Sub-Investigator: Julie Christiansen            
Sub-Investigator: Lorre Thompson            
Sponsors and Collaborators
Children's Hospitals and Clinics of Minnesota
Investigators
Principal Investigator: Katie Fenlon, PT Children's Hospitals and Clinics of MN
  More Information

No publications provided

Responsible Party: Children's Hospitals and Clinics of Minnesota ( Laurie Blumberg-Romero/Research Administrator )
Study ID Numbers: 0807-068
Study First Received: September 11, 2008
Last Updated: March 19, 2009
ClinicalTrials.gov Identifier: NCT00751647     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Children's Hospitals and Clinics of Minnesota:
CF

Study placed in the following topic categories:
Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis
Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

Additional relevant MeSH terms:
Pathologic Processes
Digestive System Diseases
Genetic Diseases, Inborn
Respiratory Tract Diseases
Cystic Fibrosis
Fibrosis
Lung Diseases
Infant, Newborn, Diseases
Pancreatic Diseases

ClinicalTrials.gov processed this record on May 07, 2009